Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Bromelain Derived from pineapples, Bromelain is a potent digestive enzyme with anti-obesity properties
This decline contributes to multiple hallmarks of aging including decreased muscle mass and strength, increased fat accumulation, reduced bone density, impaired cognitive function, and compromised immune system performance
Orforglipron, developed by Eli Lilly, is a next-generation oral non-peptide small molecule GLP-1 agonist that has completed Phase 3 trials and filed for FDA approval
Routine cell or tissue lysate Western blot protocol For most 20-100 kDa targets in whole-cell lysate or tissue lysate
On April 1, 2026, the FDA approved orforglipron (Foundayo) by Eli Lilly for adults with obesity or overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity
More interestingly, AFB1 could inhibit the electron transport chain function, affect ATP synthesis and dysregulate key genes in mitochondria (243), leading to genetic mutations and DNA damage (244)
